Navigation Links
BrightFocus Foundation announces 55 new grantees in Alzheimer's and vision research
Date:7/10/2014

Clarksburg, MDBrightFocus Foundation, a nonprofit organization funding cutting-edge, innovative research on Alzheimer's disease and the vision diseases of glaucoma and macular degeneration, today announced the recipients of new research grant awards, offered to 55 scientists in 19 U.S. states, the District of Columbia, and five foreign countries. See http://www.brightfocus.org/Grants2014.

With these latest grants, BrightFocus has now provided more than $8.7 million in research funding in 2014.

The research projects funded this year reflect a range of study interests and new technologies, with many scientists trying to unlock the clues to earlier detection and treatment of these diseases, before irreversible harm is done.

Demographic pressures bring a new urgency to the search for cures. Members of the large Baby Boom generation are now at the age where they are increasingly caring for elderly parents with these diseases, or facing an increased risk of acquiring one or more of these diseases themselves.

"The financial and emotional costs of these conditions to our country, and around the world, will be enormous," said BrightFocus President and CEO Stacy Pagos Haller. "We believe that finding a way to slow, prevent, and treat brain and eye diseases must be a national priority."

BrightFocus occupies a unique position in the world of research, identifying the most promising, early-stage research opportunities and offering "seed money" that helps new projects get off the ground. The Foundation has provided $140.3 million in research funding to date, awarding nearly $35 million for research on diseases of mind and sight in the last four years alone.

"With the continued strain and uncertainties facing federal funding for research, it is vital that nonprofits like BrightFocus help to keep the scientific pipeline funded," said Haller.

Here are some of the trends in this year's research topics:

Alzheimer's Disease Research

Alzheimer's disease is a progressive and degenerative brain disorder that ultimately ends in death. A recent study by the Rush Alzheimer's Disease Center in Chicago suggests that Alzheimer's may be a much more common cause of death than previously thoughtperhaps the third leading cause of death in the U.S.

The main hope for preventing Alzheimer's disease lies in intervening earlier than is now possible, since symptoms appear after irreversible brain damage has occurred. Scientists thus are exploring the possible pathways to earlier detection. A number of grantees are studying the early activity of the tau protein, associated with the accumulation of misshaped proteins that resemble "tangles" in the brain. Both tau "tangles" and beta amyloid "plaques" are sometimes, but not always, linked to the cognitive impairments found in Alzheimer's disease.

Other scientists are looking at different genes involved in masterminding the interplay of proteins seen in Alzheimer's disease. Researchers are trying to understand why cells in the healthy brain are able to expel excess tau and beta amyloid proteins before they become toxic, and what goes wrong with that cellular "housekeeping" in Alzheimer's disease. Still others are studying similarities between Alzheimer's disease and other diseases, and devising ways to test "repurposed drugs" that have already been approved by the Food and Drug Administration for other diseases, but may hold promise with Alzheimer's.

National Glaucoma Research

Glaucoma is a group of diseases that damage the eye's optic nerve and can result in vision loss and blindness. With early detection, the disease can be managed to protect against vision lossyet an estimated half of the three million people with glaucoma in the U.S. may not know they have the disease.

Researchers are trying to improve ways to study the changes in eye pressure that occur with this disease. Automated gene mapping techniques will search for genes involved in inherited forms of glaucoma. Scientists will target a new glaucoma gene controlling a protein linked to the death of retinal ganglion cells. High-resolution scans will help pinpoint genes associated with changes in optic nerves. Other scientists are studying the damaged eye drainage structures in glaucoma, or investigating whether other factors, including the immune system or changes in blood flow, hold the clue to defeating this disease.

Macular Degeneration Research

Macular degeneration is the leading cause of legal blindness in most developed countries and in the U.S. affects as many as 11 million people. The disease damages the macula, which is the part of the eye providing sharp, central vision needed for seeing objects clearly.

Six of the sixteen new grantees studying this disease are looking at how inflammation plays a role in early macular degeneration. The disease may develop after immune cells become activated when they should not be, causing damage. Still other researchers are examining early detection and diagnosis using advanced imaging techniques. Scientists are also experimenting with cell-based and gene-based therapies that might help reverse the changes leading to early disease, before retinal injury and vision loss occur.


'/>"/>

Contact: Alice L. Kirkman
akirkman@brightfocus.org
240-778-5563
BrightFocus Foundation
Source:Eurekalert

Related biology news :

1. BrightFocus Foundation announces $7.2 million in grants for Alzheimers and vision disease research
2. Kessler Foundation implements Ekso Bionics first commercial robotic exoskeleton
3. Renowned geneticist R. Rodney Howell receives ACMG Foundation Lifetime Achievement Award
4. John A. Kaufman named 2012 Dotter Lecturer by Society of Interventional Radiology Foundation
5. Genzyme/ACMG Foundation Genetics Training Award in Clinical Biochemical Genetics announced
6. 2012 ACMG Foundation/Signature Genomic Laboratories Travel Award winner announced
7. ASBMB wins National Science Foundation grant to enhance K-12 science education
8. UF receives $1 million from Keck Foundation to study mechanisms of inherited disease
9. Merkin Family Foundation to fund next generation of Broad Institute scientists
10. Michael J. Fox Foundation grant to Dr. Samuel Young will provide Parkinsons drug development tools
11. New York Stem Cell Foundation scientist grows bone from human embryonic stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 1, 2016   SoftServe , a global ... , an electrocardiogram (ECG) biosensor analysis system for ... IoT asset. The smart system ensures device-to-device communication ... wheel and mobile devices to easily ,recognize, and ... As vehicle technology advances, so too must the ...
(Date:11/30/2016)... -- higi SH llc (higi) announced today the launch ... industry thought-leaders and celebrity influencers looking to encourage, ... steps to live healthier, more active lives. ... built the largest self-screening health station network in ... have conducted over 185 million biometric screenings.  The ...
(Date:11/29/2016)... , Nov. 29, 2016   Neurotechnology ... and object recognition technologies, today released FingerCell ... fingerprint recognition solutions that run on low-power, ... template using less than 128KB of memory, ... devices that have limited on-board resources, such ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... AskLinkerReports.com has published a report on ... Industry 2016 Market Research Report. From a basic outline of ... are all covered in the report. This report projects investment ... of the Amyloglucosidase industry. ... , , Complete ...
(Date:12/8/2016)... Portland, Oregon (PRWEB) , ... December 08, 2016 ... ... modules and the FrontPanel SDK that provide essential device-to-computer interconnect using USB or ... do not require FrontPanel support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module ...
(Date:12/8/2016)... Maryland (PRWEB) , ... December ... ... announces the commercial launch of flexible packaging for their exceptionally efficient ... disposable bag system extends RoosterBio’s portfolio of bioprocess media products engineered to ...
(Date:12/8/2016)... , Dec. 8, 2016  HedgePath Pharmaceuticals, Inc. ... discovers, develops and plans to commercialize innovative therapeutics ... of common stock were approved for trading on ... trading on the OTCQX, effective today, under the ... the OTCQX market, companies must meet high financial ...
Breaking Biology Technology: